Tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part A and B: Advanced Solid Malignancies.
货号（Catalog No.）
CSD00156
通用名INN
Tremelimumab
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Tremelimumab is under investigation for the treatment of Mesothelioma, Liver Cancer, Liver Neoplasms, Liver Cell Caricinoma, and HepatoCellular Carcinoma. Tremelimumab has been investigated in Part C: Malignant Mesothelioma and Part A and B: Advanced Solid Malignancies.
别名(Alternative names)
CP-675,CP-675,206,CP-675206 clone 11.2.1
靶点;物种(Specificity target name;species)
CTLA4/CD152[Homo sapiens]
种类(Species)
Homo sapiens
受体鉴定(Receptor identification)
IgG2-kappa
化学信息
CAS
745013-59-6
存储条件(Storage)
store at -80°C
Note
For research use only. Not suitable for clinical or therapeutic use.
...
产品展厅
